Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 16/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | PHLPP1 | O60346 | 1/20 | 0.37 |
| ▸ | ILK | Q13418 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | TTPA | P49638 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22551377 | 0.71 | — | — | |
| SCHEMBL9579473 | 0.71 | AKT1 (0.40) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL22551346 | 0.70 | — | — | |
| SCHEMBL22551376 | 0.66 | ALOX5 (0.31) | — | |
| SCHEMBL9717087 | 0.65 | LMNA (0.50) | AKT1LMNAMAPTMEN1GSTP1 | |
| SCHEMBL9717095 | 0.65 | LMNA (0.50) | AKT1LMNAMAPTMEN1GSTP1 | |
| SCHEMBL13138998 | 0.65 | LMNA (0.50) | AKT1LMNAMAPTMEN1GSTP1 | |
| SCHEMBL20910001 | 0.62 | GABRA1 (0.39) | LMNA | |
| SCHEMBL2737162 | 0.62 | AKT1 (0.33) | AKT1PDPK1PHLPP1ILKLMNA | |
| SCHEMBL215615 | 0.61 | LMNA (0.33) | AKT1PDPK1PHLPP1ILKLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113891882-B | Process for producing dihydroisoxazole | 组合化学工业株式会社 | 2024-11-26 | — | — | CN | disclosed |
| CN-112004805-B | Process for producing 5, 5-disubstituted-4, 5-dihydroisoxazoles | 组合化学工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-117396464-A | Process for producing aldehyde compound and dihydroisoxazole compound | 组合化学工业株式会社 | 2024-01-12 | — | — | CN | disclosed |
| US-11753384-B2 | Production method for 5,5-di-substituted-4,5-dihydroisoxazole | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2023-09-12 | — | — | US | disclosed |
| EP-3789382-B1 | PRODUCTION METHOD FOR 5,5-DI-SUBSTITUTED-4,5-DIHYDROISOXAZOLE | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2023-07-05 | — | — | EP | disclosed |
| WO-2023054702-A1 | ALDEHYDE COMPOUND PRODUCTION METHOD AND DIHYDROISOXAZOLE COMPOUND PRODUCTION METHOD | クミアイ化学工業株式会社 | 2023-04-06 | — | — | WO | disclosed |
| EP-3733652-B1 | METHOD FOR PRODUCING THIOCARBOXAMIDINE SALT COMPOUND | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2022-10-12 | — | — | EP | disclosed |
| CN-111491926-B | Novel method for producing 5, 5-disubstituted-4, 5-dihydroisoxazole | 组合化学工业株式会社 | 2022-07-15 | — | — | CN | disclosed |
| EP-3725782-B1 | NOVEL METHOD FOR PRODUCING 5,5-DISUBSTITUTED-4,5-DIHYDROISOXAZOLE | KUMIAI CHEMICAL INDUSTRY CO (JP) | 2022-06-22 | — | — | EP | disclosed |
| CN-113891882-A | Method for producing dihydroisoxazole | 组合化学工业株式会社 | 2022-01-04 | — | — | CN | disclosed |
| EP-3789382-A1 | PRODUCTION METHOD FOR 5,5-DI-SUBSTITUTED-4,5-DIHYDROISOXAZOLE | Kumiai Chemical Industry Co., Ltd. (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20210047280-A1 | NOVEL METHOD FOR PRODUCING 5, 5-DISUBSTITUTED-4, 5-DIHYDROISOXAZOLE | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2021-02-18 | — | — | US | disclosed |
| WO-2020251006-A1 | METHOD FOR PRODUCING DIHYDROISOXAZOLE | クミアイ化学工業株式会社 | 2020-12-17 | — | — | WO | disclosed |
| CN-112004805-A | Process for producing 5, 5-disubstituted-4, 5-dihydroisoxazoles | 组合化学工业株式会社 | 2020-11-27 | — | — | CN | disclosed |
| US-20200369631-A1 | METHOD FOR PRODUCING THIOCARBOXAMIDINE SALT COMPOUND | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2020-11-26 | — | — | US | disclosed |
| US-10844024-B1 | Method for producing thiocarboxamidine salt compound | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 2020-11-24 | — | — | US | disclosed |
| EP-3733652-A1 | METHOD FOR PRODUCING THIOCARBOXAMIDINE SALT COMPOUND | Kumiai Chemical Industry Co., Ltd. (JP) | 2020-11-04 | — | — | EP | disclosed |
| EP-3725782-A1 | NOVEL METHOD FOR PRODUCING 5,5-DISUBSTITUTED-4,5-DIHYDROISOXAZOLE | Kumiai Chemical Industry Co., Ltd. (JP) | 2020-10-21 | — | — | EP | disclosed |
| CN-111542514-A | Process for producing mercaptoformamidinate compound | 组合化学工业株式会社 | 2020-08-14 | — | — | CN | disclosed |
| CN-111491926-A | Novel method for producing 5, 5-disubstituted-4, 5-dihydroisoxazoles | 组合化学工业株式会社 | 2020-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047280-A1 | NOVEL METHOD FOR PRODUCING 5, 5-DISUBSTITUTED-4, 5-DIHYDROISOXAZOLE | CYP3A5, CYP4X1, SQLE | AKT1 4706/4885PDPK1 2038/4885PHLPP1 4530/4885 |
| US-10844024-B1 | Method for producing thiocarboxamidine salt compound | TST, CBR3, NISCH | AKT1 1541/4885PDPK1 3507/4885PHLPP1 4800/4885 |
| US-11753384-B2 | Production method for 5,5-di-substituted-4,5-dihydroisoxazole | CYP3A5, CYP3A4, DHPS | AKT1 4304/4885PDPK1 1878/4885PHLPP1 4121/4885 |
| US-20200369631-A1 | METHOD FOR PRODUCING THIOCARBOXAMIDINE SALT COMPOUND | TST, CBR3, NISCH | AKT1 1541/4885PDPK1 3507/4885PHLPP1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.